share_log

Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus

Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus

Viatris 宣布发布了 20亿 CARE 研究结果,显示 Cenerimod 在中度至重度狼疮中的有效性。
Benzinga ·  12/18 20:03

Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases

CARE研究的生物标志物数据描述了cenerimod在系统性红斑狼疮中的作用机制,该数据也发表在《风湿病年鉴》上。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发